Locus (coeruleus) minoris resistentiae in pathogenesis of alzheimer’s disease

Current Alzheimer Research

Volumn 11, Issue 10, 2014, Pages 992-1001

  Mravec, Boris ^a,b   Lejavova, Katarina ^a,b   Cubinkova, Veronika ^c  

^a Faculty of Medicine of Comenius University and University Hospital Bratislava   (Slovakia)

^b INSTITUTE OF EXPERIMENTAL ENDOCRINOLOGY   (Slovakia)

^c INSTITUTE OF NEUROIMMUNOLOGY   (Slovakia)

Author keywords

Alzheimer's disease; Blood brain barrier; Locus coeruleus; Neuroinflammation; Plasticity; Tau protein

Indexed keywords

TAU PROTEIN;

ALZHEIMER DISEASE; ARTICLE; BLOOD BRAIN BARRIER; CELL SURVIVAL; HUMAN; LOCUS CERULEUS; NERVE CELL PLASTICITY; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROANATOMY; NEUROPHYSIOLOGY; NONHUMAN; PATHOGENESIS; ADRENERGIC NERVE CELL; ANIMAL; COMPLICATION; ENCEPHALITIS; PATHOLOGY;

ADRENERGIC NEURONS; ALZHEIMER DISEASE; ANIMALS; ENCEPHALITIS; HUMANS; LOCUS COERULEUS; NERVE DEGENERATION;

EID: 84919595466     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205011666141107130505     Document Type: Article

References (151)

1. Thies W, Bleiler L. Alzheimer's disease facts and figures. Alzheimers Dement 9(2): 208-45 (2013).
2. Nagy Z, Hindley NJ, Braak H, Braak E, Yilmazer-Hanke DM, Schultz C, et al. The progression of Alzheimer's disease from limbic regions to the neocortex: clinical, radiological and pathological relationships. Dement Geriatr Cogn Disord 10(2): 115-20 (1999).
3. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 256(5054): 184-5 (1992).
4. Wischik CM, Novak M, Thogersen HC, Edwards PC, Runswick MJ, Jakes R, et al. Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer disease. Proc Natl Acad Sci USA 85(12): 4506-10 (1988).
5. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 90(5): 1977-81 (1993).
6. Ramanan VK, Saykin AJ. Pathways to neurodegeneration: mechanistic insights from GWAS in Alzheimer's disease, Parkinson's disease, and related disorders. Am J Neurodegener Dis 2(3): 145-75 (2013).
7. Armstrong RA. What causes alzheimer's disease? Folia Neuropathol 51(3): 169-88 (2013).
8. Giacobini E, Gold G. Alzheimer disease therapy-moving from amyloid-beta to tau. Nat Rev Neurol 9(12): 677-86 (2013).
9. Rentz DM, Locascio JJ, Becker JA, Moran EK, Eng E, Buckner RL, et al. Cognition, reserve, and amyloid deposition in normal aging. Ann Neurol 67(3): 353-64 (2010).
10. Nelson PT, Jicha GA, Schmitt FA, Liu H, Davis DG, Mendiondo MS, et al. Clinicopathologic correlations in a large Alzheimer disease center autopsy cohort: neuritic plaques and neurofibrillary tangles "do count" when staging disease severity. J Neuropathol Exp Neurol 66(12): 1136-46 (2007).
11. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 42(3 Pt 1): 631-9 (1992).
12. Zilkova M, Zilka N, Kovac A, Kovacech B, Skrabana R, Skrabanova M, et al. Hyperphosphorylated truncated protein tau induces caspase-3 independent apoptosis-like pathway in the Alzheimer's disease cellular model. J Alzheimers Dis 23(1): 161-9 (2011).
13. Kovacech B, Novak M. Tau truncation is a productive posttranslational modification of neurofibrillary degeneration in Alzheimer's disease. Curr Alzheimer Res 7(8): 708-16 (2010).
14. Guillozet-Bongaarts AL, Garcia-Sierra F, Reynolds MR, Horowitz PM, Fu Y, Wang T, et al. Tau truncation during neurofibrillary tangle evolution in Alzheimer's disease. Neurobiol Aging 26(7): 1015-22 (2005).
15. Mondragon-Rodriguez S, Basurto-Islas G, Santa-Maria I, Mena R, Binder LI, Avila J, et al. Cleavage and conformational changes of tau protein follow phosphorylation during Alzheimer's disease. Int J Exp Pathol 89(2): 81-90 (2008).
16. Braak H, Zetterberg H, Del Tredici K, Blennow K. Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloidbeta changes occur before increases of tau in cerebrospinal fluid. Acta Neuropathol 126(5): 631-41 (2013).
17. Mez J, Stern RA, McKee AC. Chronic traumatic encephalopathy: where are we and where are we going? Curr Neurol Neurosci Rep 13(12): 407 (2013).
18. McKee AC, Daneshvar DH, Alvarez VE, Stein TD. The neuropathology of sport. Acta Neuropathol 127(1): 29-51 (2014).
19. Zilka N, Filipcik P, Koson P, Fialova L, Skrabana R, Zilkova M, et al. Truncated tau from sporadic Alzheimer's disease suffices to drive neurofibrillary degeneration in vivo. FEBS Lett 580(15): 3582-8 (2006).
20. Gandy S, Ikonomovic MD, Mitsis E, Elder G, Ahlers ST, Barth J, et al. Chronic traumatic encephalopathy: clinical-biomarker correlations and current concepts in pathogenesis. Mol Neurodegener 9(1): 37 (2014).
21. Cui B, Zhu L, She X, Wu M, Ma Q, Wang T, et al. Chronic noise exposure causes persistence of tau hyperphosphorylation and formation of NFT tau in the rat hippocampus and prefrontal cortex. Exp Neurol 238(2): 122-9 (2012).
22. Sy M, Kitazawa M, Medeiros R, Whitman L, Cheng D, Lane TE, et al. Inflammation induced by infection potentiates tau pathological features in transgenic mice. Am J Pathol 178(6): 2811-22 (2011).
23. Spolcova A, Mikulaskova B, Krskova K, Gajdosechova L, Zorad S, Olszanecki R, et al. Deficient hippocampal insulin signaling and augmented Tau phosphorylation is related to obesity- and ageinduced peripheral insulin resistance: a study in Zucker rats. BMC Neurosci 15(1): 111 (2014).
24. Novak P, Prcina M, Kontsekova E. Tauons and prions: infamous cousins? J Alzheimers Dis 26(3): 413-30 (2011).
25. Sanders DW, Kaufman SK, DeVos SL, Sharma AM, Mirbaha H, Li A, et al. Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron 82(6): 1271-88 (2014).
26. de Calignon A, Polydoro M, Suarez-Calvet M, William C, Adamowicz DH, Kopeikina KJ, et al. Propagation of tau pathology in a model of early Alzheimer's disease. Neuron 73(4): 685-97 (2012).
27. Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol 70(11): 960-9 (2011).
28. O'Donnell J, Zeppenfeld D, McConnell E, Pena S, Nedergaard M. Norepinephrine: a neuromodulator that boosts the function of multiple cell types to optimize CNS performance. Neurochem Res 37(11): 2496-512 (2012).
29. Hertz L, Lovatt D, Goldman SA, Nedergaard M. Adrenoceptors in brain: cellular gene expression and effects on astrocytic metabolism and [Ca(2+)]i. Neurochem Int 57(4): 411-20 (2010).
30. Marien MR, Colpaert FC, Rosenquist AC. Noradrenergic mechanisms in neurodegenerative diseases: a theory. Brain Res Brain Res Rev 45(1): 38-78 (2004).
31. Toussay X, Basu K, Lacoste B, Hamel E. Locus coeruleus stimulation recruits a broad cortical neuronal network and increases cortical perfusion. J Neurosci 33(8): 3390-401 (2013).
32. Bekar LK, Wei HS, Nedergaard M. The locus coeruleusnorepinephrine network optimizes coupling of cerebral blood volume with oxygen demand. J Cereb Blood Flow Metab 32(12): 2135-45 (2012).
33. Robertson SD, Plummer NW, de Marchena J, Jensen P. Developmental origins of central norepinephrine neuron diversity. Nat Neurosci 16(8): 1016-23 (2013).
34. Freedman R, Foote SL, Bloom FE. Histochemical characterization of a neocortical projection of the nucleus locus coeruleus in the squirrel monkey. J Comp Neurol 164(2): 209-31 (1975).
35. Foote SL, Bloom FE, Aston-Jones G. Nucleus locus ceruleus: new evidence of anatomical and physiological specificity. Physiol Rev 63(3): 844-914 (1983).
36. Szabadi E. Functional neuroanatomy of the central noradrenergic system. J Psychopharmacol 27(8): 659-93 (2013).
37. Audet MA, Doucet G, Oleskevich S, Descarries L. Quantified regional and laminar distribution of the noradrenaline innervation in the anterior half of the adult rat cerebral cortex. J Comp Neurol 274(3): 307-18 (1988).
38. Holets VR, Hokfelt T, Rokaeus A, Terenius L, Goldstein M. Locus coeruleus neurons in the rat containing neuropeptide Y, tyrosine hydroxylase or galanin and their efferent projections to the spinal cord, cerebral cortex and hypothalamus. Neuroscience 24(3): 893-906 (1988).
39. Abercrombie ED, Jacobs BL. Single-unit response of noradrenergic neurons in the locus coeruleus of freely moving cats. I. Acutely presented stressful and nonstressful stimuli. J Neurosci 7(9): 2837-43 (1987).
40. Aston-Jones G, Bloom FE. Activity of norepinephrine-containing locus coeruleus neurons in behaving rats anticipates fluctuations in the sleep-waking cycle. J Neurosci 1(8): 876-86 (1981).
41. Sara SJ, Bouret S. Orienting and reorienting: the locus coeruleus mediates cognition through arousal. Neuron 76(1): 130-41 (2012).
42. Samuels ER, Szabadi E. Functional neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function part I: principles of functional organisation. Curr Neuropharmacol 6(3): 235-53 (2008).
43. Swiergiel AH, Takahashi LK, Rubin WW, Kalin NH. Antagonism of corticotropin-releasing factor receptors in the locus coeruleus attenuates shock-induced freezing in rats. Brain Res 587(2): 263-8 (1992).
44. Smagin GN, Harris RB, Ryan DH. Corticotropin-releasing factor receptor antagonist infused into the locus coeruleus attenuates immobilization stress-induced defensive withdrawal in rats. Neurosci Lett 220(3): 167-70 (1996).
45. Valentino RJ, Page ME, Curtis AL. Activation of noradrenergic locus coeruleus neurons by hemodynamic stress is due to local release of corticotropin-releasing factor. Brain Res 555(1): 25-34 (1991).
46. Samuels ER, Szabadi E. Functional neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function part II: physiological and pharmacological manipulations and pathological alterations of locus coeruleus activity in humans. Curr Neuropharmacol 6(3): 254-85 (2008).
47. Avery MC, Dutt N, Krichmar JL. A large-scale neural network model of the influence of neuromodulatory levels on working memory and behavior. Front Comput Neurosci 7: 133 (2013).
48. Linster C, Nai Q, Ennis M. Nonlinear effects of noradrenergic modulation of olfactory bulb function in adult rodents. J Neurophysiol 105(4): 1432-43 (2011).
49. Berridge CW, Schmeichel BE, Espana RA. Noradrenergic modulation of wakefulness/arousal. Sleep Med Rev 16(2): 187-97 (2012).
50. Clark CN, Warren JD. A hypnic hypothesis of Alzheimer's disease. Neurodegener Dis 12(4): 165-76 (2013).
51. Mabbott NA, MacPherson GG. Prions and their lethal journey to the brain. Nat Rev Microbiol 4(3): 201-11 (2006).
52. Ramage SN, Anthony IC, Carnie FW, Busuttil A, Robertson R, Bell JE. Hyperphosphorylated tau and amyloid precursor protein deposition is increased in the brains of young drug abusers. Neuropathol Appl Neurobiol 31(4): 439-48 (2005).
53. Rosenberg PA. Catecholamine toxicity in cerebral cortex in dissociated cell culture. J Neurosci 8(8): 2887-94 (1988).
54. Burke WJ, Li SW, Zahm DS, Macarthur H, Kolo LL, Westfall TC, et al. Catecholamine monoamine oxidase a metabolite in adrenergic neurons is cytotoxic in vivo. Brain Res 891(1-2): 218-27 (2001).
55. Arnold SE, Hyman BT, Flory J, Damasio AR, Van Hoesen GW. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cereb Cortex 1(1): 103-16 (1991).
56. Wilcock GK, Esiri MM, Bowen DM, Hughes AO. The differential involvement of subcortical nuclei in senile dementia of Alzheimer's type. J Neurol Neurosurg Psychiatry 51(6): 842-9 (1988).
57. Mann DM, Yates PO, Marcyniuk B. Correlation between senile plaque and neurofibrillary tangle counts in cerebral cortex and neuronal counts in cortex and subcortical structures in Alzheimer's disease. Neurosci Lett 56(1): 51-5 (1985).
58. Braak H, Del Tredici K. The pathological process underlying Alzheimer's disease in individuals under thirty. Acta Neuropathol 121(2): 171-81 (2011).
59. Brunnstrom H, Friberg N, Lindberg E, Englund E. Differential degeneration of the locus coeruleus in dementia subtypes. Clin Neuropathol 30(3): 104-10 (2011).
60. Zweig RM, Ross CA, Hedreen JC, Steele C, Cardillo JE, Whitehouse PJ, et al. The neuropathology of aminergic nuclei in Alzheimer's disease. Ann Neurol 24(2): 233-42 (1988).
61. Trillo L, Das D, Hsieh W, Medina B, Moghadam S, Lin B, et al. Ascending monoaminergic systems alterations in Alzheimer's disease. Translating basic science into clinical care. Neurosci Biobehav Rev 37(8): 1363-79 (2013).
62. Bondareff W, Mountjoy CQ, Roth M, Rossor MN, Iversen LL, Reynolds GP, et al. Neuronal degeneration in locus ceruleus and cortical correlates of Alzheimer disease. Alzheimer Dis Assoc Disord 1(4): 256-62 (1987).
63. Zarow C, Lyness SA, Mortimer JA, Chui HC. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol 60(3): 337-41 (2003).
64. Bondareff W, Mountjoy CQ, Roth M. Loss of neurons of origin of the adrenergic projection to cerebral cortex (nucleus locus ceruleus) in senile dementia. Neurology 32(2): 164-8 (1982).
65. Marcyniuk B, Mann DM, Yates PO. The topography of cell loss from locus caeruleus in Alzheimer's disease. J Neurol Sci 76(2-3): 335-45 (1986).
66. Adolfsson R, Gottfries CG, Roos BE, Winblad B. Changes in the brain catecholamines in patients with dementia of Alzheimer type. Br J Psychiatry 135: 216-23 (1979).
67. Iversen LL, Rossor MN, Reynolds GP, Hills R, Roth M, Mountjoy CQ, et al. Loss of pigmented dopamine-beta-hydroxylase positive cells from locus coeruleus in senile dementia of Alzheimer's type. Neurosci Lett 39(1): 95-100 (1983).
68. Kaddurah-Daouk R, Rozen S, Matson W, Han X, Hulette CM, Burke JR, et al. Metabolomic changes in autopsy-confirmed Alzheimer's disease. Alzheimers Dement 7(3): 309-17 (2011).
69. Merrill CA, Jonsson MA, Minthon L, Ejnell H, H CsS, Blennow K, et al. Vagus nerve stimulation in patients with Alzheimer's disease: Additional follow-up results of a pilot study through 1 year. J Clin Psychiatry 67(8): 1171-8 (2006).
70. Sjogren MJ, Hellstrom PT, Jonsson MA, Runnerstam M, Silander HC, Ben-Menachem E. Cognition-enhancing effect of vagus nerve stimulation in patients with Alzheimer's disease: a pilot study. J Clin Psychiatry 63(11): 972-80 (2002).
71. Shen H, Fuchino Y, Miyamoto D, Nomura H, Matsuki N. Vagus nerve stimulation enhances perforant path-CA3 synaptic transmission via the activation of beta-adrenergic receptors and the locus coeruleus. Int J Neuropsychopharmacol 15(4): 523-30 (2012).
72. Ruffoli R, Giorgi FS, Pizzanelli C, Murri L, Paparelli A, Fornai F. The chemical neuroanatomy of vagus nerve stimulation. J Chem Neuroanat 42(4): 288-96 (2011).
73. Manta S, Dong J, Debonnel G, Blier P. Enhancement of the function of rat serotonin and norepinephrine neurons by sustained vagus nerve stimulation. J Psychiatry Neurosci 34(4): 272-80 (2009).
74. Cunningham JT, Mifflin SW, Gould GG, Frazer A. Induction of c- Fos and DeltaFosB immunoreactivity in rat brain by Vagal nerve stimulation. Neuropsychopharmacology 33(8): 1884-95 (2008).
75. Szot P, White SS, Greenup JL, Leverenz JB, Peskind ER, Raskind MA. Compensatory changes in the noradrenergic nervous system in the locus ceruleus and hippocampus of postmortem subjects with Alzheimer's disease and dementia with Lewy bodies. J Neurosci 26(2): 467-78 (2006).
76. Kandel ER, Schwartz JH. Molecular biology of learning: modulation of transmitter release. Science 218(4571): 433-4 (1982).
77. Hatanpaa K, Isaacs KR, Shirao T, Brady DR, Rapoport SI. Loss of proteins regulating synaptic plasticity in normal aging of the human brain and in Alzheimer disease. J Neuropathol Exp Neurol 58(6): 637-43 (1999).
78. DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann Neurol 27(5): 457-64 (1990).
79. Kirkwood A, Rozas C, Kirkwood J, Perez F, Bear MF. Modulation of long-term synaptic depression in visual cortex by acetylcholine and norepinephrine. J Neurosci 19(5): 1599-609 (1999).
80. Katsuki H, Izumi Y, Zorumski CF. Noradrenergic regulation of synaptic plasticity in the hippocampal CA1 region. J Neurophysiol 77(6): 3013-20 (1997).
81. Neuman RS, Harley CW. Long-lasting potentiation of the dentate gyrus population spike by norepinephrine. Brain Res 273(1): 162-5 (1983).
82. Bramham CR, Bacher-Svendsen K, Sarvey JM. LTP in the lateral perforant path is beta-adrenergic receptor-dependent. Neuroreport 8(3): 719-24 (1997).
83. Turrigiano GG, Leslie KR, Desai NS, Rutherford LC, Nelson SB. Activity-dependent scaling of quantal amplitude in neocortical neurons. Nature 391(6670): 892-6 (1998).
84. Counts SE, Mufson EJ. Noradrenaline activation of neurotrophic pathways protects against neuronal amyloid toxicity. J Neurochem 113(3): 649-60 (2010).
85. Simonini MV, Polak PE, Sharp A, McGuire S, Galea E, Feinstein DL. Increasing CNS noradrenaline reduces EAE severity. J Neuroimmune Pharmacol 5(2): 252-9 (2010).
86. Alzheimer A, Stelzmann RA, Schnitzlein HN, Murtagh FR. An English translation of Alzheimer's 1907 paper, "Uber eine eigenartige Erkankung der Hirnrinde". Clin Anat 8(6): 429-31 (1995).
87. Lue LF, Brachova L, Civin WH, Rogers J. Inflammation, A beta deposition, and neurofibrillary tangle formation as correlates of Alzheimer's disease neurodegeneration. J Neuropathol Exp Neurol 55(10): 1083-8 (1996).
88. Rogers J, Luber-Narod J, Styren SD, Civin WH. Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer's disease. Neurobiol Aging 9(4): 339-49 (1988).
89. Akiyama H, Mori H, Saido T, Kondo H, Ikeda K, McGeer PL. Occurrence of the diffuse amyloid beta-protein (Abeta) deposits with numerous Abeta-containing glial cells in the cerebral cortex of patients with Alzheimer's disease. Glia 25(4): 324-31 (1999).
90. McGeer PL, Itagaki S, Tago H, McGeer EG. Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci Lett 79(1-2): 195-200 (1987).
91. DiPatre PL, Gelman BB. Microglial cell activation in aging and Alzheimer disease: partial linkage with neurofibrillary tangle burden in the hippocampus. J Neuropathol Exp Neurol 56(2): 143-9 (1997).
92. Edison P, Archer HA, Gerhard A, Hinz R, Pavese N, Turkheimer FE, et al. Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiol Dis 32(3): 412-9 (2008).
93. Zilka N, Stozicka Z, Kovac A, Pilipcinec E, Bugos O, Novak M. Human misfolded truncated tau protein promotes activation of microglia and leukocyte infiltration in the transgenic rat model of tauopathy. J Neuroimmunol 209(1-2): 16-25 (2009).
94. Bellucci A, Westwood AJ, Ingram E, Casamenti F, Goedert M, Spillantini MG. Induction of inflammatory mediators and microglial activation in mice transgenic for mutant human P301S tau protein. Am J Pathol 165(5): 1643-52 (2004).
95. Fishel MA, Watson GS, Montine TJ, Wang Q, Green PS, Kulstad JJ, et al. Hyperinsulinemia provokes synchronous increases in central inflammation and beta-amyloid in normal adults. Arch Neurol 62(10): 1539-44 (2005).
96. Sparks Stein P, Steffen MJ, Smith C, Jicha G, Ebersole JL, Abner E, et al. Serum antibodies to periodontal pathogens are a risk factor for Alzheimer's disease. Alzheimers Dement 8(3): 196-203 (2012).
97. Glushakova OY, Johnson D, Hayes RL. Delayed increases in microvascular pathology after experimental traumatic brain injury are associated with prolonged inflammation, blood-brain barrier disruption, and progressive white matter damage. J Neurotrauma 31(13): 1180-93 (2014).
98. Jamieson GA, Maitland NJ, Wilcock GK, Craske J, Itzhaki RF. Latent herpes simplex virus type 1 in normal and Alzheimer's disease brains. J Med Virol 33(4): 224-7 (1991).
99. Balin BJ, Gerard HC, Arking EJ, Appelt DM, Branigan PJ, Abrams JT, et al. Identification and localization of Chlamydia pneumoniae in the Alzheimer's brain. Med Microbiol Immunol 187(1): 23-42 (1998).
100. Chavarria A, Cardenas G. Neuronal influence behind the central nervous system regulation of the immune cells. Front Integr Neurosci 7: 64 (2013).
101. Feinstein DL, Galea E, Reis DJ. Norepinephrine suppresses inducible nitric oxide synthase activity in rat astroglial cultures. J Neurochem 60(5): 1945-8 (1993).
102. Heneka MT, O'Banion MK. Inflammatory processes in Alzheimer's disease. J Neuroimmunol 184(1-2): 69-91 (2007).
103. O'Sullivan JB, Ryan KM, Curtin NM, Harkin A, Connor TJ. Noradrenaline reuptake inhibitors limit neuroinflammation in rat cortex following a systemic inflammatory challenge: implications for depression and neurodegeneration. Int J Neuropsychopharmacol 12(5): 687-99 (2009).
104. Feinstein DL, Heneka MT, Gavrilyuk V, Dello Russo C, Weinberg G, Galea E. Noradrenergic regulation of inflammatory gene expression in brain. Neurochem Int 41(5): 357-65 (2002).
105. Jardanhazi-Kurutz D, Kummer MP, Terwel D, Vogel K, Thiele A, Heneka MT. Distinct adrenergic system changes and neuroinflammation in response to induced locus ceruleus degeneration in APP/PS1 transgenic mice. Neuroscience 176: 396-407 (2011).
106. Heneka MT, Nadrigny F, Regen T, Martinez-Hernandez A, Dumitrescu-Ozimek L, Terwel D, et al. Locus ceruleus controls Alzheimer's disease pathology by modulating microglial functions through norepinephrine. Proc Natl Acad Sci USA 107(13): 6058-63 (2010).
107. Cardoso FL, Brites D, Brito MA. Looking at the blood-brain barrier: molecular anatomy and possible investigation approaches. Brain Res Rev 64(2): 328-63 (2010).
108. Benarroch EE. Blood-brain barrier: recent developments and clinical correlations. Neurology 78(16): 1268-76 (2012).
109. Claudio L. Ultrastructural features of the blood-brain barrier in biopsy tissue from Alzheimer's disease patients. Acta Neuropathol 91(1): 6-14 (1996).
110. Zipser BD, Johanson CE, Gonzalez L, Berzin TM, Tavares R, Hulette CM, et al. Microvascular injury and blood-brain barrier leakage in Alzheimer's disease. Neurobiol Aging 28(7): 977-86 (2007).
111. Marques F, Sousa JC, Sousa N, Palha JA. Blood--brain-barriers in aging and in Alzheimer's disease. Mol Neurodegener 8(1): 38 (2013).
112. Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57(2): 178-201 (2008).
113. Harik SI. Blood-brain barrier sodium/potassium pump: modulation by central noradrenergic innervation. Proc Natl Acad Sci USA 83(11): 4067-70.(1986).
114. Harik SI, McGunigal T, Jr. The protective influence of the locus ceruleus on the blood-brain barrier. Ann Neurol 15(6): 568-74 (1984).
115. Kalinin S, Feinstein DL, Xu HL, Huesa G, Pelligrino DA, Galea E. Degeneration of noradrenergic fibres from the locus coeruleus causes tight-junction disorganisation in the rat brain. Eur J Neurosci 24(12): 3393-400 (2006).
116. Wilson RS, Evans DA, Bienias JL, Mendes de Leon CF, Schneider JA, Bennett DA. Proneness to psychological distress is associated with risk of Alzheimer's disease. Neurology 61(11): 1479-85 (2003).
117. Rissman RA, Lee KF, Vale W, Sawchenko PE. Corticotropinreleasing factor receptors differentially regulate stress-induced tau phosphorylation. J Neurosci 27(24): 6552-62 (2007).
118. Pavlides C, Watanabe Y, McEwen BS. Effects of glucocorticoids on hippocampal long-term potentiation. Hippocampus 3(2): 183-92 (1993).
119. Bodnoff SR, Humphreys AG, Lehman JC, Diamond DM, Rose GM, Meaney MJ. Enduring effects of chronic corticosterone treatment on spatial learning, synaptic plasticity, and hippocampal neuropathology in young and mid-aged rats. J Neurosci 15(1 Pt 1): 61-9 (1995).
120. Cunningham ET, Jr., Sawchenko PE. Anatomical specificity of noradrenergic inputs to the paraventricular and supraoptic nuclei of the rat hypothalamus. J Comp Neurol 274(1): 60-76 (1988).
121. Koegler-Muly SM, Owens MJ, Ervin GN, Kilts CD, Nemeroff CB. Potential corticotropin-releasing factor pathways in the rat brain as determined by bilateral electrolytic lesions of the central amygdaloid nucleus and the paraventricular nucleus of the hypothalamus. J Neuroendocrinol 5(1): 95-8 (1993).
122. Filipcik P, Novak P, Mravec B, Ondicova K, Krajciova G, Novak M, et al. Tau protein phosphorylation in diverse brain areas of normal and CRH deficient mice: up-regulation by stress. Cell Mol Neurobiol 32(5): 837-45 (2012).
123. Rissman RA, Staup MA, Lee AR, Justice NJ, Rice KC, Vale W, et al. Corticotropin-releasing factor receptor-dependent effects of repeated stress on tau phosphorylation, solubility, and aggregation. Proc Natl Acad Sci USA 109(16): 6277-82 (2012).
124. Carroll JC, Iba M, Bangasser DA, Valentino RJ, James MJ, Brunden KR, et al. Chronic stress exacerbates tau pathology, neurodegeneration, and cognitive performance through a corticotropin-releasing factor receptor-dependent mechanism in a transgenic mouse model of tauopathy. J Neurosci 31(40): 14436-49 (2011).
125. Campbell SN, Zheng C, Monte L, Roe AD, Rice KC, Tache Y, et al. Increased Tau Phosphorylation and Aggregation in Mice Overexpressing Corticotropin-Releasing Factor. J Alzheimers Dis (2014).
126. Oliveira JR, Nishimura AL, Lemos RR, Zatz M. The genetics of Alzheimer's disease in Brazil: 10 years of analysis in a unique population. J Mol Neurosci 37(1): 74-9 (2009).
127. Loerch PM, Lu T, Dakin KA, Vann JM, Isaacs A, Geula C, et al. Evolution of the aging brain transcriptome and synaptic regulation. PLoS ONE 3(10): e3329 (2008).
128. Palacios JM, Hoyer D, Cortes R. alpha 1-Adrenoceptors in the mammalian brain: similar pharmacology but different distribution in rodents and primates. Brain Res 419(1-2): 65-75 (1987).
129. German DC, Manaye KF, White CL, 3rd, Woodward DJ, McIntire DD, Smith WK, et al. Disease-specific patterns of locus coeruleus cell loss. Ann Neurol 32(5): 667-76 (1992).
130. Jackson WS. Selective vulnerability to neurodegenerative disease: the curious case of Prion Protein. Dis Model Mech 7(1): 21-9 (2014).
131. Vina J, Lloret A. Why women have more Alzheimer's disease than men: gender and mitochondrial toxicity of amyloid-beta peptide. J Alzheimers Dis 20(2): S527-33 (2010).
132. Valentino RJ, Van Bockstaele E, Bangasser D. Sex-specific cell signaling: the corticotropin-releasing factor receptor model. Trends Pharmacol Sci 34(8): 437-44 (2013).
133. Kuskowski MA, Malone SM, Mortimer JA, Dysken MW. Smooth pursuit eye movements in dementia of the Alzheimer type. Alzheimer Dis Assoc Disord 3(3): 157-71 (1989).
134. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 215(4537): 1237-9 (1982).
135. Schliebs R, Arendt T. The cholinergic system in aging and neuronal degeneration. Behav Brain Res 221(2): 555-63 (2011).
136. Gu Q. Neuromodulatory transmitter systems in the cortex and their role in cortical plasticity. Neuroscience 111(4): 815-35 (2002).
137. Fuxe K, Dahlstrom AB, Jonsson G, Marcellino D, Guescini M, Dam M, et al. The discovery of central monoamine neurons gave volume transmission to the wired brain. Prog Neurobiol 90(2): 82-100 (2010).
138. Grinberg LT, Rub U, Ferretti RE, Nitrini R, Farfel JM, Polichiso L, et al. The dorsal raphe nucleus shows phospho-tau neurofibrillary changes before the transentorhinal region in Alzheimer's disease. A precocious onset? Neuropathol Appl Neurobiol 35(4): 406-16 (2009).
139. Nakamura S, Takemura M, Ohnishi K, Suenaga T, Nishimura M, Akiguchi I, et al. Loss of large neurons and occurrence of neurofibrillary tangles in the tuberomammillary nucleus of patients with Alzheimer's disease. Neurosci Lett 151(2): 196-9 (1993).
140. Attems J, Thomas A, Jellinger K. Correlations between cortical and subcortical tau pathology. Neuropathol Appl Neurobiol 38(6): 582-90 (2012).
141. Mann DM, Yates PO, Hawkes J. The pathology of the human locus ceruleus. Clin Neuropathol 2(1): 1-7 (1983).
142. Del Tredici K, Braak H. Dysfunction of the locus coeruleusnorepinephrine system and related circuitry in Parkinson's diseaserelated dementia. J Neurol Neurosurg Psychiatry 84(7): 774-83 (2013).
143. McMillan PJ, White SS, Franklin A, Greenup JL, Leverenz JB, Raskind MA, et al. Differential response of the central noradrenergic nervous system to the loss of locus coeruleus neurons in Parkinson's disease and Alzheimer's disease. Brain Res 1373: 240-52 (2011).
144. Chalermpalanupap T, Kinkead B, Hu WT, Kummer MP, Hammerschmidt T, Heneka MT, et al. Targeting norepinephrine in mild cognitive impairment and Alzheimer's disease. Alzheimers Res Ther 5(2): 21 (2013).
145. Appleby BS, Nacopoulos D, Milano N, Zhong K, Cummings JL. A review: treatment of Alzheimer's disease discovered in repurposed agents. Dement Geriatr Cogn Disord 35(1-2): 1-22 (2013).
146. Kim HJ, Kim W, Kong SY. Antidepressants for neuroregeneration: from depression to Alzheimer's disease. Arch Pharm Res 36(11): 1279-90 (2013).
147. Bautista-Aguilera OM, Esteban G, Bolea I, Nikolic K, Agbaba D, Moraleda I, et al. Design, synthesis, pharmacological evaluation, QSAR analysis, molecular modeling and ADMET of novel donepezil-indolyl hybrids as multipotent cholinesterase/monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease. Eur J Med Chem 75C: 82-95 (2014).
148. Noh JS, Kim EY, Kang JS, Kim HR, Oh YJ, Gwag BJ. Neurotoxic and neuroprotective actions of catecholamines in cortical neurons. Exp Neurol 159(1): 217-24 (1999).
149. Fitzgerald PJ. Is elevated norepinephrine an etiological factor in some cases of Alzheimer's disease? Curr Alzheimer Res 7(6): 506-16 (2010).
150. Saper CB, Scammell TE, Lu J. Hypothalamic regulation of sleep and circadian rhythms. Nature 437(7063): 1257-63 (2005).
151. Benarroch EE. The locus ceruleus norepinephrine system: functional organization and potential clinical significance. Neurology 73(20): 1699-704 (2009).